PharmaCyte Biotech (PMCB) Receivables - Accured (2024 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Receivables - Accured of $240766.0 for Q2 2026, up 75.1% year-over-year from $137500.0 in Q2 2025, and down 16.26% quarter-over-quarter from $287500.0 in Q4 2025.
PharmaCyte Biotech (PMCB) Receivables - Accured (2024 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Receivables - Accured for 3 consecutive years, with $240766.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables - Accured rose 75.1% year-over-year to $240766.0; the TTM figure through Apr 2026 stood at $240766.0 (up 75.1% YoY), while the FY2026 annual figure was $240766.0, up 75.1% from the prior year.
- Receivables - Accured declined to $240766.0 in Q2 2026 per PMCB's latest filing, from $287500.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $287500.0 in Q4 2025 and bottomed at $137500.0 in Q2 2024.
- Historically, Receivables - Accured has averaged $203153.2 across 3 years, with a median of $212500.0 in 2025.
- Annual changes were most pronounced in 2025 — Receivables - Accured changed 0.0% — and 2026, when it soared 75.1%.
- PharmaCyte Biotech's Receivables - Accured stood at $137500.0 in 2024, then jumped by 109.09% to $287500.0 in 2025, then decreased by 16.26% to $240766.0 in 2026.
- Business Quant data shows PMCB's Receivables - Accured at $240766.0 in Q2 2026, $287500.0 in Q4 2025, and $212500.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 240,766.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 240,766.00 |
| Apr 30, 2026 | 240,766.00 |
| Oct 31, 2025 | 287,500.00 |
| Oct 31, 2025 | 287,500.00 |
| Jul 31, 2025 | 212,500.00 |
| Jul 31, 2025 | 212,500.00 |
| Apr 30, 2025 | 137,500.00 |
| Apr 30, 2025 | 137,500.00 |
| Apr 30, 2024 | 137,500.00 |
| Apr 30, 2024 | 137,500.00 |